The US medical devices industry saw a drop of 19.7% in overall deal activity during August 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 61 deals worth $2.02bn were announced in August 2019, compared to the 12-month average of 76 deals.

Venture financing was the leading category in the month in terms of volume with 47 deals which accounted for 77.05% of all deals.

In second place was M&A with 13 deals, followed by private equity with one transaction, respectively accounting for 21.3% and 1.6% of overall deal activity in the country’s medical devices industry during the month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $1.66bn, while venture financing deals totalled $363.2m.


US medical devices industry deals in August 2019: Top deals

The top five medical devices industry deals accounted for 83.2% of the overall value during August 2019.

The combined value of the top five medical devices deals stood at $1.68bn, against the overall value of $2.02bn recorded for the month.

The top five medical devices industry deals of August 2019 tracked by GlobalData were:

1) Siemens Healthineers’ $1.1bn acquisition of Corindus Vascular Robotics

2) The $300m acquisition of SentreHEART by AtriCure

3) Hill-Rom Holdings’ $130m acquisition of Breathe Technologies

4) The $101.8m acquisition of New Aera by Inogen

5) Dreamers Fund, KPCB Green Growth Fund, Lowercase Capital, Reproductive Health Investors Alliance, TriplePoint Capital, Union Square Ventures and Y Combinator Management’s venture financing of Nurx for $52m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.